Galderma Group (GALD) Aktienübersicht
Die Galderma Group AG ist als Dermatologie-Unternehmen weltweit tätig. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 4/6 |
| Vergangene Leistung | 5/6 |
| Finanzielle Gesundheit | 4/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für GALD festgestellt.
GALD Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Galderma Group AG Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | CHF 175.95 |
| 52-Wochen-Hoch | CHF 188.25 |
| 52-Wochen-Tief | CHF 129.90 |
| Beta | -0.097 |
| 1 Monat Veränderung | 1.79% |
| 3 Monate Veränderung | 7.68% |
| 1 Jahr Veränderung | 32.49% |
| 3 Jahre Veränderung | n/a |
| 5 Jahre Veränderung | n/a |
| Veränderung seit IPO | 174.92% |
Aktuelle Nachrichten und Updates
Narrative-Update • Jul 30
GALD: Aesthetics And Dermatology Execution Will Drive Future Re Rating Conviction
Galderma Group's analyst price target has moved higher toward a CHF 200 to CHF 210 range, with analysts pointing to updated expectations for Nemluvio and injectable aesthetics, alongside adjustments to revenue growth, profit margin and future P/E assumptions. Analyst Commentary Recent research on Galderma Group highlights a clear shift toward more optimistic views, with several bullish analysts lifting price targets into the CHF 175 to CHF 210 range.
Narrative-Update • Jul 16
GALD: FDA Manufacturing Setbacks And Rich P/E Will Likely Cap Future Upside
Galderma Group's analyst price target is updated to CHF 131.68 from CHF 125.65 as analysts factor in revised fair value assumptions, including adjusted revenue growth, profit margin, and future P/E inputs, alongside recent Street target increases to as high as CHF 175. Analyst Commentary Recent Street research on Galderma Group points to a mixed tone.
Narrative-Update • Jul 01
GALD: Higher CHF Sentiment Will Test Acne Franchise Concentration Risk
Analysts have raised the Galderma Group fair value estimate by about CHF 5 to CHF 188 per share, citing updated Street research with higher CHF price targets from several major banks as support for the revised view. Analyst Commentary Recent Street research on Galderma Group has centered on a series of upward price target revisions in CHF terms, which analysts link to their reassessment of the company’s execution and potential growth options.Recent updates
Narrative-Update • Jul 30
GALD: Aesthetics And Dermatology Execution Will Drive Future Re Rating Conviction
Galderma Group's analyst price target has moved higher toward a CHF 200 to CHF 210 range, with analysts pointing to updated expectations for Nemluvio and injectable aesthetics, alongside adjustments to revenue growth, profit margin and future P/E assumptions. Analyst Commentary Recent research on Galderma Group highlights a clear shift toward more optimistic views, with several bullish analysts lifting price targets into the CHF 175 to CHF 210 range.Narrative-Update • Jul 16
GALD: FDA Manufacturing Setbacks And Rich P/E Will Likely Cap Future Upside
Galderma Group's analyst price target is updated to CHF 131.68 from CHF 125.65 as analysts factor in revised fair value assumptions, including adjusted revenue growth, profit margin, and future P/E inputs, alongside recent Street target increases to as high as CHF 175. Analyst Commentary Recent Street research on Galderma Group points to a mixed tone.Narrative-Update • Jul 01
GALD: Higher CHF Sentiment Will Test Acne Franchise Concentration Risk
Analysts have raised the Galderma Group fair value estimate by about CHF 5 to CHF 188 per share, citing updated Street research with higher CHF price targets from several major banks as support for the revised view. Analyst Commentary Recent Street research on Galderma Group has centered on a series of upward price target revisions in CHF terms, which analysts link to their reassessment of the company’s execution and potential growth options.Narrative-Update • Jun 17
GALD: Rising Execution Bar And Rich P/E Will Likely Cap Future Share Upside
Analysts have raised the Galderma Group price target by CHF 5 to CHF 125.65, citing updated assumptions on fair value, revenue growth, profit margins and forward P/E that are consistent with a recent series of target increases from major banks. Analyst Commentary Recent Street research on Galderma Group points to a cluster of higher price targets, framed around updated assumptions for earnings quality, revenue mix and P/E levels.Narrative-Update • Jun 03
GALD: Rising Optimism Will Meet Acne Franchise Concentration Risk
Analysts have lifted the Galderma Group price target by about CHF 1 to roughly CHF 183.50, reflecting updated views on fair value, slightly adjusted revenue growth and profit margin assumptions, and continued supportive research commentary across several firms. Analyst Commentary Recent research has focused on how Galderma can execute on its growth plans while justifying higher valuation ranges, with several firms adjusting price targets and ratings in quick succession.Narrative-Update • May 13
GALD: Rising Optimism Will Meet Pediatric Skin Franchise Concentration Risk
Analysts have nudged their average price target for Galderma higher by around CHF 5 to reflect updated assumptions for revenue growth, profit margins and longer term P/E expectations, following a series of recent target increases from firms such as Morgan Stanley, Citi, RBC Capital, Berenberg, H.C. Wainwright and Barclays. Analyst Commentary Recent research on Galderma Group has been active, with several firms updating their views and price targets.Narrative-Update • Apr 28
GALD: Higher Fair Value View Will Support Future Re Rating Conviction
Analysts have increased the Galderma Group fair value estimate by about CHF 48, from roughly CHF 192 to around CHF 240. They cite recent price target increases across several firms, along with support from product driven growth assumptions and a higher future P/E multiple.Narrative-Update • Apr 14
GALD: Elevated Expectations For Dermatology Franchise Will Likely Cap Future Share Upside
Analysts have raised the Galderma Group price target by CHF 7 to reflect updated expectations for revenue growth, profit margin and future P/E, supported by a series of recent CHF-based target increases from several research houses. Analyst Commentary Recent research updates show a cluster of higher CHF based price targets for Galderma Group, with several firms revising their assumptions around growth, margins and P/E multiples.Narrative-Update • Mar 31
GALD: Rising Optimism Will Meet Pediatric Skin Franchise Execution Risk
The updated analyst price target for Galderma Group moves higher to reflect Street research that cites support from products like Nemluvio, tighter profit margin assumptions, a slightly adjusted discount rate, and a modestly lower future P/E expectation across recent CHF 155 to CHF 260 target revisions. Analyst Commentary Bullish Takeaways Bullish analysts are lifting price targets into a CHF 155 to CHF 260 range, which signals higher conviction in Galderma Group's valuation support at current levels.Narrative-Update • Mar 17
GALD: High Expectations For Key Therapies Will Likely Restrain Future Share Returns
Narrative Update on Galderma Group The updated analyst price target for Galderma Group has moved higher in the latest model, aligning with recent Street target increases to CHF 155, CHF 200 and CHF 260, as analysts highlight support from products such as Nemluvio and adjustments to growth and margin assumptions. Analyst Commentary Recent Street research on Galderma Group points to a cluster of higher price targets in the CHF 155 to CHF 260 range, with different attitudes on how much upside may be left.Narrative-Update • Mar 03
GALD: Elevated Growth Assumptions Will Likely Pressure Shares Despite Raised Outlook
Analysts have raised their Galderma Group price target to CHF 195 from CHF 155, reflecting updated assumptions for revenue growth, profit margins, discount rate, and future P/E that modestly reduce estimated fair value to CHF 110.71 from CHF 111.24. Analyst Commentary The latest price target move to CHF 195 sits well above the estimated fair value of CHF 110.71, which signals that some analysts are embedding optimistic assumptions on growth and profitability.Narrative-Update • Feb 16
GALD: Higher CHF 195 Outlook Will Support Future Re Rating Conviction
Analysts have raised their price target on Galderma Group to CHF 195 from CHF 155, reflecting updated views on revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent research points to a more constructive stance on Galderma Group, with bullish analysts lifting their price targets and expressing increased confidence in the company’s execution and valuation framework.Narrative-Update • Feb 02
GALD: Higher Future P/E Assumptions Will Likely Pressure Shares Forward
Analysts have lifted their price target on Galderma Group to CHF 195 from CHF 155, citing updated assumptions that include higher fair value estimates, a slightly adjusted discount rate, revised revenue growth and profit margin expectations, and a higher future P/E multiple. Analyst Commentary The move to a CHF 195 price target is framed around updated valuation work, with higher assumed fair value, a revised discount rate, and adjusted revenue and margin assumptions.Narrative-Update • Jan 19
GALD: Raised Growth Outlook And L’Oréal Stake Increase Will Support Re Rating
Analysts have raised their blended price target range for Galderma Group to approximately CHF 195 to CHF 200 from about CHF 140 to CHF 165, citing updated fair value estimates, revised assumptions for revenue growth and profit margins, as well as a higher projected P/E multiple. Analyst Commentary Recent Street research points to a more constructive stance on Galderma Group, with several bullish analysts lifting their price targets into the CHF 140 to CHF 195 range.Narrative-Update • Jan 05
GALD: Rising Market Optimism Will Meet Execution Risk And Fairly Balanced Prospects
Analysts have made a marginal trim to their fair value estimate for Galderma Group to approximately CHF 159.55 per share, even as Street price targets have moved higher into a CHF 140 to CHF 182 range. This reflects updated views on the stock's P/E assumptions and recent research from multiple banks.Narrative-Update • Dec 14
GALD: Rising Market Optimism Will Meet Execution And Competitive Challenges Ahead
Analysts have nudged their blended price target for Galderma Group higher by approximately CHF 6, reflecting increased confidence in the companys faster than previously expected revenue growth, improving profit margins, and a slightly richer forward price-to-earnings multiple supported by a series of recent target hikes across the Street. Analyst Commentary Recent target hikes from multiple firms underscore a constructive stance on Galderma Group’s medium term outlook, with bullish analysts pointing to accelerating top line momentum and improving profitability as key drivers of upside to current valuation.Narrative-Update • Nov 30
GALD: Upward Momentum In Pricing Will Face Competitive And Execution Risks Ahead
Galderma Group's fair value estimate has been raised from CHF 150.37 to CHF 153.80. This reflects analysts' positive outlook supported by a series of recent upward price target revisions in light of expectations of continued revenue growth and stable profitability.Narrative-Update • Nov 16
GALD: Momentum In Product Approvals And Expansion Will Face Execution Challenges
Galderma Group’s analyst price target has been revised upward from CHF 149.91 to CHF 150.37. This reflects positive analyst sentiment, driven by higher recent target increases and confidence in the company’s growth prospects.Narrative-Update • Oct 31
GALD: Execution On New Aesthetic Launches And Margin Gains Will Sustain Upside
The fair value estimate for Galderma Group has been raised to CHF 149.91 from CHF 142.41. This change reflects analysts' increased confidence due to positive revisions to growth and margin forecasts, as well as a series of upward price target adjustments from major research firms.Analyseartikel • Oct 29
Is Galderma Group AG (VTX:GALD) Trading At A 40% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Galderma Group fair value estimate is CHF239 Current share...Narrative-Update • Oct 17
Global Aesthetics And Aging Trends Will Drive Expansion
The analyst price target for Galderma Group has been raised, with new estimates increasing from CHF 140.69 to CHF 142.41. This change reflects analysts' optimism on the company's outlook amid steady growth expectations and supportive recent research updates.Narrative-Update • Aug 27
Global Aesthetics And Aging Trends Will Drive Expansion
Analysts have raised Galderma Group's price target to CHF140.69, reflecting strengthened conviction in early Nemluvio traction, robust pipeline execution, and sustained market share gains across dermatology. Analyst Commentary Bullish analysts cite strong early commercial traction and blockbuster potential for Nemluvio following its recent launch.Analyseartikel • Aug 24
Is Galderma Group (VTX:GALD) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Neues Narrative • May 12
Nemluvio Launch And Global Expansion Will Shape Therapeutic Dermatology Markets
Launch of Nemluvio and international expansion in China and India are expected to significantly boost revenue growth and market share.Aktionärsrenditen
| GALD | CH Pharmaceuticals | CH Markt | |
|---|---|---|---|
| 7D | 1.1% | 2.9% | 1.5% |
| 1Y | 32.5% | 40.4% | 19.1% |
Rendite im Vergleich zur Industrie: GALD unter dem Niveau der Branche Swiss Pharmaceuticals , die im vergangenen Jahr eine Rendite von 40.4% erzielte.
Rendite vs. Markt: GALD übertraf den Markt Swiss, der im vergangenen Jahr eine Rendite von 19.1 erzielte.
Preisvolatilität
| GALD volatility | |
|---|---|
| GALD Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in CH Market | 7.7% |
| 10% least volatile stocks in CH Market | 2.1% |
Stabiler Aktienkurs: GALD hatte in den letzten 3 Monaten im Vergleich zum Swiss -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: GALDDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1981 | 7,676 | Flemming Ornskov | www.galderma.com |
Die Galderma Group AG ist ein weltweit tätiges Unternehmen im Bereich der Dermatologie. Das Unternehmen bietet ein wissenschaftlich fundiertes Portfolio von Marken und Dienstleistungen für den Dermatologiemarkt an, darunter injizierbare Ästhetik, dermatologische Hautpflege und therapeutische Dermatologie. Zu seinem Portfolio an führenden Marken gehören Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac und Loceryl in der therapeutischen Dermatologie.
Galderma Group AG's Grundlagenzusammenfassung
| GALD grundlegende Statistiken | |
|---|---|
| Marktanteil | CHF 42.29b |
| Gewinn(TTM) | CHF 697.82m |
| Umsatz(TTM) | CHF 4.79b |
58.8x
Kurs-Gewinn-Verhältnis 8.6x
Kurs-Umsatz-VerhältnisIst GALD zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| GALD Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$5.92b |
| Kosten der Einnahmen | US$1.81b |
| Bruttogewinn | US$4.11b |
| Sonstige Ausgaben | US$3.25b |
| Gewinn | US$863.00m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 3.70 |
| Bruttomarge | 69.37% |
| Nettogewinnspanne | 14.57% |
| Schulden/Eigenkapital-Verhältnis | 30.8% |
Wie hat sich GALD auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
0.2%
Aktuelle Dividendenrendite12%
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/10 18:57 |
| Aktienkurs zum Tagesende | 2026/08/10 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Galderma Group AG wird von 29 Analysten beobachtet. 17 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Yihan Li | Barclays |
| James Gordon | Barclays |
| Fulvio Cazzol | Berenberg |